InterCure Ltd. (NASDAQ:INCR) Short Interest Up 19.8% in February

InterCure Ltd. (NASDAQ:INCRGet Free Report) was the target of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 4,894 shares, a growth of 19.8% from the January 29th total of 4,086 shares. Based on an average trading volume of 40,557 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 40,557 shares, the days-to-cover ratio is currently 0.1 days.

InterCure Stock Up 2.4%

Shares of NASDAQ INCR traded up $0.02 during trading hours on Wednesday, hitting $0.85. The stock had a trading volume of 51,812 shares, compared to its average volume of 68,434. The company has a market capitalization of $38.73 million, a P/E ratio of 10.63 and a beta of 1.22. The firm’s 50-day moving average price is $0.93 and its two-hundred day moving average price is $1.28. InterCure has a 52 week low of $0.68 and a 52 week high of $1.77. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.09 and a current ratio of 1.85.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of InterCure in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

View Our Latest Analysis on INCR

About InterCure

(Get Free Report)

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.

Featured Stories

Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.